Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Follow her on Twitter @megtirrell.
Amid the battle over who benefits the most from increasing prescription drug prices, Eli Lilly CEO David Ricks says, "It's time for a change" to the system.
The new research could pose a major setback to the treatment that has has been hailed as a breakthrough.
Dr. Ned Sharpless says there's good reason to stop being so "sheepish" about uttering "cure" when it comes to cancer.
Giovanni Caforio, Bristol-Myers Squibb chairman and CEO, talks about the company's partnership with Nektar and latest immunotherapy treatments.
Mark Alles, Celgene chairman and CEO discusses personalized immunotherapy treatment for cancer patients, investor confidence, and other therapies in development.
The updates from ASCO can be practice-changing for doctors, life-changing for patients, and — for investors — market-moving.
CNBC's Meg Tirrell provides a preview of this year's meeting of the American Society of Clinical Oncology (ASCO).
U.S. stock futures were higher Friday morning after the major averages all closed in the red Thursday, CNBC's Meg Tirrell reports.
As would-be parents push back parenthood, companies that provide baby products are feeling the pinch.
The error led to an overestimation of the amount of prescription fentanyl being used in the U.S.